CN101479275B - 2-(取代的-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂 - Google Patents

2-(取代的-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂 Download PDF

Info

Publication number
CN101479275B
CN101479275B CN2007800236807A CN200780023680A CN101479275B CN 101479275 B CN101479275 B CN 101479275B CN 2007800236807 A CN2007800236807 A CN 2007800236807A CN 200780023680 A CN200780023680 A CN 200780023680A CN 101479275 B CN101479275 B CN 101479275B
Authority
CN
China
Prior art keywords
compound
compounds
amino
alkyl
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800236807A
Other languages
English (en)
Chinese (zh)
Other versions
CN101479275A (zh
Inventor
H·德科克
T·H·M·琼克斯
P·J·G·M·布曼茨
S·J·拉斯特
I·迪里恩克
J·E·鲍梅斯特
G·A·E·范特克卢斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Tibotec BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec BVBA filed Critical Tibotec BVBA
Publication of CN101479275A publication Critical patent/CN101479275A/zh
Application granted granted Critical
Publication of CN101479275B publication Critical patent/CN101479275B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN2007800236807A 2006-06-23 2007-06-22 2-(取代的-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂 Active CN101479275B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06116003.2 2006-06-23
EP06116003 2006-06-23
PCT/EP2007/056235 WO2007147884A1 (en) 2006-06-23 2007-06-22 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors

Publications (2)

Publication Number Publication Date
CN101479275A CN101479275A (zh) 2009-07-08
CN101479275B true CN101479275B (zh) 2012-03-07

Family

ID=37596252

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800236807A Active CN101479275B (zh) 2006-06-23 2007-06-22 2-(取代的-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂

Country Status (30)

Country Link
US (1) US8202887B2 (enExample)
EP (1) EP2035432B1 (enExample)
JP (1) JP5232776B2 (enExample)
KR (1) KR101419320B1 (enExample)
CN (1) CN101479275B (enExample)
AP (1) AP2069A (enExample)
AR (1) AR061619A1 (enExample)
AT (1) ATE544769T1 (enExample)
AU (1) AU2007262943B2 (enExample)
BR (1) BRPI0713487B1 (enExample)
CA (1) CA2653233C (enExample)
CL (1) CL2007001826A1 (enExample)
CY (1) CY1112971T1 (enExample)
DK (1) DK2035432T3 (enExample)
EA (1) EA016387B1 (enExample)
ES (1) ES2381129T3 (enExample)
IL (1) IL195381A (enExample)
JO (1) JO2841B1 (enExample)
MX (1) MX2009000160A (enExample)
MY (1) MY146805A (enExample)
NZ (1) NZ573286A (enExample)
PE (1) PE20080342A1 (enExample)
PL (1) PL2035432T3 (enExample)
PT (1) PT2035432E (enExample)
SI (1) SI2035432T1 (enExample)
TW (1) TWI415851B (enExample)
UA (1) UA96445C2 (enExample)
UY (1) UY30416A1 (enExample)
WO (1) WO2007147884A1 (enExample)
ZA (1) ZA200810350B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
SG186820A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht- 2 -ylacetic acid derivatives to treat aids
BR112012033689A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais
US9024038B2 (en) * 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
ES2615734T3 (es) * 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
MX2014005002A (es) 2012-04-20 2014-07-09 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih.
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1525962A (zh) * 2001-02-14 2004-09-01 ̩���ؿ�ҩƷ���޹�˾ 广谱的2-(取代-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂
CN1604803A (zh) * 2001-12-12 2005-04-06 泰博特克药品有限公司 细胞色素p450依赖性蛋白酶抑制剂的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545518A1 (en) * 2002-08-02 2005-06-29 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1525962A (zh) * 2001-02-14 2004-09-01 ̩���ؿ�ҩƷ���޹�˾ 广谱的2-(取代-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂
CN1604803A (zh) * 2001-12-12 2005-04-06 泰博特克药品有限公司 细胞色素p450依赖性蛋白酶抑制剂的组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dominique L.N.G. Surleraux et al..Design of Hiv-1 Protease Inhibitors Active on Multidrug-Resistant Virus.《J.Med.Chem.》.2005,第48卷(第6期),1965-1973. *

Also Published As

Publication number Publication date
ATE544769T1 (de) 2012-02-15
CA2653233A1 (en) 2007-12-27
PT2035432E (pt) 2012-04-24
PE20080342A1 (es) 2008-04-25
JP2009541272A (ja) 2009-11-26
AP2069A (en) 2009-12-08
CA2653233C (en) 2015-09-29
PL2035432T3 (pl) 2012-07-31
IL195381A (en) 2013-01-31
AU2007262943B2 (en) 2012-04-12
KR20090024257A (ko) 2009-03-06
BRPI0713487B1 (pt) 2022-07-26
EP2035432B1 (en) 2012-02-08
BRPI0713487A2 (enExample) 2012-11-13
AU2007262943A1 (en) 2007-12-27
TWI415851B (zh) 2013-11-21
MX2009000160A (es) 2009-01-23
SI2035432T1 (sl) 2012-06-29
MY146805A (en) 2012-09-28
US8202887B2 (en) 2012-06-19
BRPI0713487A8 (pt) 2018-01-02
WO2007147884A1 (en) 2007-12-27
DK2035432T3 (da) 2012-05-14
CY1112971T1 (el) 2016-04-13
NZ573286A (en) 2011-09-30
IL195381A0 (en) 2009-08-03
KR101419320B1 (ko) 2014-07-14
JO2841B1 (en) 2014-09-15
AP2008004679A0 (en) 2008-12-31
HK1125633A1 (en) 2009-08-14
US20090209583A1 (en) 2009-08-20
CN101479275A (zh) 2009-07-08
ZA200810350B (en) 2010-05-26
UY30416A1 (es) 2008-01-31
EA016387B1 (ru) 2012-04-30
ES2381129T3 (es) 2012-05-23
EA200970052A1 (ru) 2009-04-28
EP2035432A1 (en) 2009-03-18
TW200817416A (en) 2008-04-16
AR061619A1 (es) 2008-09-10
CL2007001826A1 (es) 2008-01-18
JP5232776B2 (ja) 2013-07-10
UA96445C2 (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
CN101479275B (zh) 2-(取代的-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂
US20150344444A1 (en) Bet-protein-inhibiting dihydroxyquinoxalinones
EA025322B1 (ru) Производные дигидробензооксазина и дигидропиридооксазина
AU2015293578A1 (en) Phenyl and tertbutylacetic acid substituted pyridinones having anti-HIV effects
EA009590B1 (ru) 2-аминобензоксазолсульфонамидные ингибиторы вич-протеазы широкого спектра
WO2000059913A1 (en) Novel thiazolobenzimidazole derivatives
KR100872029B1 (ko) 광범위 2-(치환된-아미노)-벤즈옥사졸 설폰아미드 ｈｉｖ프로테아제 저해제
ZA200501223B (en) Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
EA010908B1 (ru) Ингибиторы вич-протеазы на основе замещённых бензизоксазолсульфонамидов широкого спектра действия
JP5279503B2 (ja) Ｈｉｖプロテアーゼインヒビターとしての置換アミノフェニルスホンアミド化合物
EP2029526B1 (en) Lysine related derivatives as hiv aspartyl protease inhibitors
KR20040093119A (ko) 광범위 치환된 벤즈이미다졸 설폰아미드 ｈｉｖ프로테아제 저해제
JP5210876B2 (ja) Ｈｉｖプロテアーゼインヒビターとしてのアミノフェニルスホンアミド誘導体
HK1125633B (en) 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
BR112019019494B1 (pt) Compostos, composições farmacêuticas e usos para o tratamento de doenças parasitárias
BR112019019494A2 (pt) compostos e métodos para o tratamento de doenças parasitárias

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: IRELAND JANSSEN R + D COMPANY

Free format text: FORMER OWNER: JANSSEN R + D IRELAND

Effective date: 20150724

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TIBOTEC PHARM LTD.

Free format text: FORMER NAME: TIBOTEC NV

Owner name: JANSSEN R + D IRELAND

Free format text: FORMER NAME: TIBOTEC PHARM LTD.

CP01 Change in the name or title of a patent holder

Address after: The Irish Village

Patentee after: JANSSEN R&D IRELAND

Address before: The Irish Village

Patentee before: TIBOTEC PHARMACEUTICALS

Address after: The Irish Village

Patentee after: TIBOTEC PHARMACEUTICALS

Address before: The Irish Village

Patentee before: TIBOTEC PHARMACEUTICALS Ltd.

TR01 Transfer of patent right

Effective date of registration: 20150724

Address after: The Irish Village

Patentee after: JANSSEN R&D IRELAND

Address before: The Irish Village

Patentee before: JANSSEN R&D IRELAND